financetom
IXHL
financetom
/
Healthcare
/
IXHL
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Incannex Healthcare LimitedIXHL
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications.

The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol.

It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.

In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials.

Incannex Hea

Latest News >
What's Going On With REE Automotive Stock Tuesday?
What's Going On With REE Automotive Stock Tuesday?
Mar 18, 2025
REE Automotive Ltd. ( REE ) shares are moving lower on Tuesday after the company announced the pricing of a $27 million registered direct offering. What To Know: The company is pricing 6,376,631 shares at $4.25 per share. REE intends to use the net proceeds for working capital and general corporate purposes. What Else: REE entered into a non-binding memorandum...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.
Mar 18, 2025
11:10 AM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: GOOGL announced its largest-ever acquisition, planning to acquire cloud security platform Wiz for $32B in cash, significantly above rumors of $23B a year earlier. The deal, expected to close in...
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
Mar 18, 2025
11:07 AM EDT, 03/18/2025 (MT Newswires) -- European equities traded in the US as American depositary receipts were lower late Tuesday morning, declining 0.13% to 1,438.81 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies ( DBVT ) and Genfit ( GNFT ) , which rose 6.8% and 3.7% respectively....
Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Alphabet Inc.
Mar 18, 2025
11:05 AM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: GOOG announced its largest-ever acquisition, planning to acquire cloud security platform Wiz for $32B in cash, significantly above rumors of $23B a year earlier. The deal, expected to close in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved